D-二聚体与接受PD-1/PD-L1抑制剂治疗的晚期肿瘤患者长期预后的关系:一项Meta分析  

Association between D-dimer and the long-term prognosis of advanced cancer patients receiving PD-1/PD-L1 inhibitors:A meta-analysis

作　　者：叶倩 刘申香 Ye Qian;Liu Shenxiang(Yangzhou Center for Disease Control and Prevention,Yangzhou 225001,China;Department of Oncology,Affiliated Hospital of Yangzhou University,Yangzhou 225100,China)

机构地区：[1]扬州市疾病预防控制中心,江苏扬州225001 [2]扬州大学附属医院肿瘤科,江苏扬州225100

出　　处：《临床荟萃》2025年第2期101-106,共6页Clinical Focus

摘　　要：目的本研究旨在分析治疗前D-二聚体水平和接受PD-1/PD-L1抑制剂治疗的晚期肿瘤患者长期预后的关系。方法在中国知网、万方、维普、Pubmed、Web of Science、Cochrane Library等数据库检索截止至2024年10月20日发表的相关文献,最终纳入6篇文献进行分析。结果在接受PD-1/PD-L1抑制剂治疗的晚期肿瘤患者中,与正常D-二聚体水平的患者相比,高D-二聚体水平患者的无进展生存期(progression free survival,PFS)(单因素分析:HR=1.89,95%CI:1.33~2.67,P=0.0004;多因素分析:HR=1.79,95%CI:1.18~2.72,P=0.006)和总生存期(overall survival,OS)显著缩短(单因素分析:HR=2.02,95%CI:1.60~2.56,P<0.00001;多因素分析:HR=2.08,95%CI:1.63~2.65,P<0.00001)。结论D-二聚体可作为预测接受PD-1/PD-L1抑制剂治疗肿瘤患者预后的潜在生物标志物。Objective The study aims to analyze the associations between pretreatment D-dimer(D-D)levels and the long-term prognosis of advanced cancer patients receiving programmed death-1/programmed death-ligand 1(PD-1/PD-L1)inhibitors.Methods Relevant literatures published up to October 20,2024,were retrieved from databases including China National Knowledge Infrastructure(CNKI),Wanfang,VIP,Pubmed,Web of Science,and Cochrane Library.Six literatures were ultimately included in the analysis.Results The advanced cancer patients receiving PD-1/PD-L1 inhibitors with high D-D levels had significantly shorter progression free survival(PFS)(univariate analysis:HR=1.89,95%CI:1.33-2.67,P=0.0004;multivariate analysis:HR=1.79,95%CI:1.18-2.72,P=0.006)and overall survival(OS)(univariate analysis:HR=2.02,95%CI:1.60-2.56,P<0.00001;multivariate analysis:HR=2.08,95%CI:1.63-2.65,P<0.00001)than those with normal D-D levels.Conclusion D-D may serve as a potential biomarker for predicting the prognosis of advanced cancer patients receiving PD-1/PD-L1 inhibitors.

关 键 词：D-二聚体 免疫治疗 预后 生物标志物 

分 类 号：R730.51[医药卫生—肿瘤]